Thermo Fisher Scientific (NYSE:TMO) Releases Q3 2025 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) updated its third quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 5.460-5.510 for the period, compared to the consensus earnings per share estimate of 5.521. The company issued revenue guidance of -. Thermo Fisher Scientific also updated its FY 2025 guidance to 22.220-22.840 EPS.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMO. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Stock Up 0.8%

NYSE TMO traded up $3.58 during trading hours on Friday, hitting $478.61. The company's stock had a trading volume of 4,191,526 shares, compared to its average volume of 2,512,662. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a market capitalization of $180.67 billion, a PE ratio of 27.68, a price-to-earnings-growth ratio of 2.25 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.38 and a debt-to-equity ratio of 0.65. The company's 50-day simple moving average is $412.43 and its two-hundred day simple moving average is $470.68.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.37 EPS. Research analysts anticipate that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 491 shares of the medical research company's stock after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC's holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter. Institutional investors own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.